Innovative Targeting Solutions Inc. Extends Research Collaboration with Amgen

Burnaby, BC – February 19th, 2014 – Innovative Targeting Solutions Inc. (ITS), the developer of the next generation protein engineering technology (HuTARG), today announced the extension of its research collaboration with Amgen Inc. (Thousand Oaks, CA) that allows Amgen to internalize ITS’ HuTARG technology. Under the terms of the agreement, ITS is entitled to specific license payments and development milestones.

About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG technology. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit

Paul Kang
Tel: 604|433-6779

ITS-Amgen Press Release 2014-02-19